Evidence for the Presence of a Proteinase-Activated Receptor Distinct From the Thrombin Receptor in Vascular Endothelial Cells
- 1 April 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 78 (4) , 581-588
- https://doi.org/10.1161/01.res.78.4.581
Abstract
The thrombin receptor was the first cloned G protein–coupled receptor reported to be activated by proteolytic cleavage of its extracellular amino terminus. A second proteinase-activated receptor (PAR-2) was cloned recently and expressed in Xenopus laevis oocytes. PAR-2 was activated by trypsin and by a peptide (SLIGRL) derived from the new amino terminus. Since PAR-2 mRNA was detected in highly vascularized organs, we compared the physiological functions of the thrombin receptor and PAR-2 in vascular endothelium. Thrombin and trypsin both elicited endothelium-dependent relaxations in prostaglandin F2α (PGF2α)–contracted strips of porcine coronary artery. Whereas high doses of both thrombin or trypsin (10 U/mL) caused homologous desensitization, trypsin caused further relaxation of thrombin-desensitized tissues. Thrombin and PAR-2–derived peptides (SFLLRN and SLIGRL) both induced endothelium-dependent relaxations in PGF2α-contracted porcine coronary arteries. SFLLRN or SLIGRL (30 μmol/L) also showed homologous desensitization but not cross desensitization. In the presence of the NO synthase inhibitor NG-monomethyl-l-arginine (1 mmol/L), both SFLLRN- and SLIGRL-induced relaxations were partially inhibited. SFLLRN elicited weak contraction in coronary arteries without endothelium, whereas SLIGRL had no effect. Intravenous injection of SFLLRN (1 mg/kg, bolus) into anesthetized rats elicited a transient depressor response followed by pronounced pressor response. In contrast, intravenous administration of SLIGRL (1 mg/kg, bolus) produced only a marked depressor response. Consistent with the in vivo data, SFLLRN contracted the endothelium-rubbed rat aortic rings and aggregated human platelets in vitro, whereas SLIGRL had no effect. The finding that both trypsin and SLIGRL induced endothelium-dependent relaxations indicates the presence of PAR-2 on endothelial cells. In addition, both trypsin and SLIGRL elicited relaxations in thrombin- or SFLLRN-desensitized tissue, suggesting that PAR-2 is distinct from thrombin receptor in vascular endothelium. The lack of PAR-2–mediated platelet aggregation or smooth muscle contraction suggested it might not share the pathogenic properties associated with the thrombin receptor in the vasculature.Keywords
This publication has 17 references indexed in Scilit:
- Molecular Cloning and Functional Expression of the Gene Encoding the Human Proteinase‐Activated Receptor 2European Journal of Biochemistry, 1995
- The Mouse Proteinase-activated Receptor-2 cDNA and GeneJournal of Biological Chemistry, 1995
- Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surfaceNature, 1994
- A 14 amino acid peptide derived from the amino terminus of the cleaved thrombin receptor elevates intracellular calcium and stimulates prostacyclin production in human endothelial cellsBiochemical and Biophysical Research Communications, 1991
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991
- The Endothelium — Modulator of Vascular Smooth-Muscle ToneNew England Journal of Medicine, 1988
- Vascular endothelium, haemostasis and thrombosisBlood Reviews, 1988
- Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotoninNature, 1983
- An improved method for washing of human platelets with prostacyclinThrombosis Research, 1983
- Coronary Vascular Reactivity After Acute Myocardial IschemiaScience, 1982